跳转至内容
Merck
所有图片(1)

Key Documents

View All Documentation

P0108

Sigma-Aldrich

FPT 抑制剂I，1 X 1MG

≥98% (HPLC), solid

别名:

5-[[5-溴-2-[（2-溴苯基）甲氧基]苯基]亚甲基] -2-硫代-4-噻唑烷酮, 再生肝3的磷酸酶，抑制剂I

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C17H11Br2NO2S2
CAS号:
893449-38-2
分子量:
485.21
MDL號碼:
MFCD11045303
分類程式碼代碼:
12352200
PubChem物質ID:
329820016
NACRES:
NA.77

化驗

≥98% (HPLC)

形狀

solid

儲存條件

protect from light

顏色

yellow

溶解度

DMSO: >10 mg/mL
H2O: <2 mg/mL

儲存溫度

−20°C

SMILES 字串

Brc1ccc(OCc2ccccc2Br)c(c1)\C=C3\SC(=S)NC3=O

InChI

1S/C17H11Br2NO2S2/c18-12-5-6-14(22-9-10-3-1-2-4-13(10)19)11(7-12)8-15-16(21)20-17(23)24-15/h1-8H,9H2,(H,20,21,23)/b15-8+

InChI 密鑰

HXNBAOLVPAWYLT-OVCLIPMQSA-N

應用

PRL-3抑制剂I已被用作再生肝磷酸酶-3 (PRL-3)的抑制剂：
  • 检测其对经典霍奇金淋巴瘤细胞存活的影响
  • 用于人脐静脉内皮细胞成管实验
  • 用于检测其对神经嵴细胞迁移的影响

生化／生理作用

PRL-3抑制剂I是一种罗丹宁衍生物，其对再生肝3磷酸酶（PRL-3）的IC50值为0.9 μM，PRL-3是一种非经典的蛋白质酪氨酸磷酸酶，最近被证明与癌症转移有关。 PRL-3抑制剂I在基于细胞的测定中可降低B16F10黑色素瘤细胞的侵袭性。

特點和優勢

《受体分类和信号转导》手册的 磷蛋白磷酸酶（酪氨酸） 页面有该化合物的介绍。想要浏览手册的其他页面， 请单击此处。

儲存類別代碼

11 - Combustible Solids

水污染物質分類（WGK）

WGK 3

個人防護裝備

dust mask type N95 (US), Eyeshields, Gloves

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Jianliang Xu et al.
PloS one, 6(11), e27165-e27165 (2011-11-11)
Phosphatase of regenerating liver 3 (PRL-3) is known to be overexpressed in many tumors, and its transcript level is high in the vasculature and endothelial cells of malignant tumor tissue. However, the mechanism(s) underlying its enhanced expression and its function
Ying-Qian Lu et al.
Stem cell research, 34, 101354-101354 (2019-01-06)
The human iPS cell line, hiPS-SPG76 (FJMUi001-A), derived from skin fibroblasts from a 42-year-old male hereditary spastic paraplegia patient carrying compound heterozygous p.P498L (c.1493C > T) and p.R618W (c.1852C > T) mutations in the CAPN1 gene, was generated by non-integrative reprogramming vectors encoding OCT3/4
E G Garcia et al.
Leukemia, 35(3), 679-690 (2020-07-02)
T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive malignancy of thymocytes and is largely driven by the NOTCH/MYC pathway. Yet, additional oncogenic drivers are required for transformation. Here, we identify protein tyrosine phosphatase type 4 A3 (PRL3) as a collaborating
Jin Hee Ahn et al.
Bioorganic & medicinal chemistry letters, 16(11), 2996-2999 (2006-03-15)
A series of rhodanine derivatives was synthesized and evaluated for their ability to inhibit PRL-3. Benzylidene rhodanine derivative showed good biological activity, while compound 5e was the most active in this series exhibiting an IC50 value of 0.9 microM in
Magnus Aassved Hjort et al.
Experimental hematology & oncology, 7, 8-8 (2018-04-14)
Phosphatase of regenerating liver-3 (PRL-3) is implicated in oncogenesis of hematological and solid cancers. PRL-3 expression increases metastatic potential, invasiveness and is associated with poor prognosis. With this study, we aimed to show a possible oncogenic role of PRL-3 in
查看所有相关文献

商品

Phosphoprotein Phosphatases (Tyrosine)

Protein tyrosine phosphatases' catalytic mechanism involves transient phosphorylation.

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门